Inhalation Sciences Newsletter - The latest medical and business news from Inhalation Sciences
December 11, 2017
INHALABLE VACCINES & THE FIGHT AGAINST TB: DDL2017 HIGHLIGHTS
It’s the largest, most important event in Europe’s pulmonary drug delivery calendar—this year there were more visitors, and research posters, than ever at the Drug Delivery to the Lungs (DDL) Conference, Edinburgh, December 6-8. What were the highlights?
READ MORE: http://www.inhalation.se/en/inhalable-vaccines-the-fight-against-tb-ddl2017-highlights/
ISAB’S IN-VITRO TECHNOLOGY XPOSEALI® GRANTED PATENT IN CHINA
Inhalation Sciences’ patent application for XposeALI®, the company's unique, proprietary module for aerosol exposure of cells, has been approved in China. The product patent, which includes the design of the product, applies until the end of 2033. Inhalation Sciences’ products are protected by a total of 6 patent families.
READ MORE: http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseId=2743176
ISAB RESEARCH CONTRACT IN FORMAMP PROJECT ON ANTIBIOTIC RESISTANCE EXTENDED BY 1.2 MSEK.
Antibiotic resistance is one of the most pressing health concerns on the planet. The EU research project FORMAMP is exploring ways of using Antimicrobial Peptides (AMPs) combined with other nanoformulation strategies, to prevent it. Inhalation Sciences has been contracted to carry out an additional series of studies for the project, extending its role and research revenues.
READ MORE: http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseId=2726862
ASTRAZENECA REPORT FINDS PRECISEINHALE REDUCES THE RISK OF FAILURE WHEN DEVELOPING INHALED DRUGS
New research released by Astra Zeneca at the Association of Inhalation Toxicologists (AIT) Conference in Copenhagen, Denmark, October 26-27 shows that PreciseInhale can reduce risk and speed up drug development: “dose levels could be selected with confidence before moving into the toxicology study, reducing the risk…inherent with this class of drugs.”
READ MORE AT: http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseId=2711691
To see this Newsletter as a complete PDF go to http://www.inhalation.se/en/news/ or http://www.inhalation.se/nyheter/
For more information about Inhalation Sciences please contact:
Fredrik Sjövall, CEO
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.